New Legislations on Generics and Biosimilars Brewing in Congress

Buffery, Dalia
April 2009
American Health & Drug Benefits;Apr/May2009, Vol. 2 Issue 3, p120
Academic Journal
The article reports on various bills being introduced in the 111th Congress, which proposes new legislations on generic drugs and biosimilars in the U.S. The H.R. 1706 bill, Protecting Access to Generic Drugs Act, introduced by Representative Bobby Rush, proposes to prohibit brand name drug companies from compensating generic drug companies to delay the entry of generics into the market. The H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act, reintroduced by Representative Henry Waxman, aims to provide the licensing of biosimilar and biogeneric biological products. Also, the H.R. 1548, Pathway for Biosimilars Act, reintroduced by Representative Anna Eshoo, weights the needs of patients and stakeholder companies.


Related Articles

  • Authors Revisit Hatch-Waxman Act. Wechsler, Jill // Pharmaceutical Executive;Jun2002 Supplement, Vol. 23, p20 

    Reports on the opposition of U.S. Senator Orrin Hatch (R., Utah) to the proposed changes to the Hatch-Waxman Act for the pharmaceutical industry in 2002. Discussion on the proposed changes; Reason of U.S. Representative Henry Waxman (D., Cal.) for disagreeing with Hatch; Details on the call of...

  • Hatch-Waxman Act II: biologics legislation.  // Drug Store News;10/9/2006, Vol. 28 Issue 13, p20 

    The article reports on the plan of U.S. Representative Henry Waxman to introduce a legislation that would establish a clear pathway for the approval of generic biologic products also known as bionergics or biosimilars. The said bill will give benefit to all uninsured American patients that are...

  • Bill seeks to curb online pharmacies. Dickinson, James G. // Medical Marketing & Media;Apr2004, Vol. 39 Issue 4, p15 

    Reports that a legislation to curb the growing sale of prescription drugs over the Internet without a valid prescription has been introduced by House Government Reform Committee chairman Tom Davis and ranking minority member Henry Waxman. Amendment to the Food, Drug and Cosmetic Act;...

  • Toxic Chemicals Safety Act.  // Congressional Digest;Oct2010, Vol. 89 Issue 8, p234 

    The article provides information about H.R. 5820, or the Toxic Chemicals Safety Act (TSCA), which is a legislative bill introduced by Democratic U.S. Representatives Henry Waxman from California and Bobby L. Rush from Illinois. TSCA amendments include the topics of chemical substances, safety...

  • Should the House Pass H.R. 2427, the Pharmaceutical Market Access Act? CON. Eshoo, Anna G. // Congressional Digest;Nov2003, Vol. 82 Issue 9, p281 

    Presents a speech delivered by Honorable Anna G. Eshoo, Representative of the Fourteenth District of California during the House floor debate on H.R. 247, the Pharmaceutical Market Access Act on July 24, 2003.

  • FDA charged with a decline in enforcement. McGuire, Stephen // Medical Marketing & Media;Aug2006, Vol. 41 Issue 8, p32 

    The article reports on the criticism issued by Congressman Henry Waxman involving the lack of enforcement of drug safety issues by the U.S. Food and Drug Administration. He released the results of a congressional investigation charging that the agency's enforcement of drug laws has declined...

  • WASTE.  // Pollution Engineering;Sep2010, Vol. 42 Issue 9, p10 

    The article reports on the introduction of Toxic Chemicals Safety Act of 2010 (H.R. 5820) (TCSA), by Representatives Bobby Rush and Henry A. Waxman, which is intended to strengthen TCSA regulations in the U.S.

  • Hatch-Waxman compromise bill in need of reform, author contends. Frederick, James // Drug Store News;2/17/2003, Vol. 25 Issue 2, p35 

    Reports on the need to reform the Hatch-Waxman compromise bill for the generic drug industry in the U.S. Achievements of Congressman Henry Waxman; Plan of Waxman to eliminate the key provisions in the law; Balance between access and innovation in the industry.

  • Rep. Waxman to PhRMA: Hands off agencies.  // Drug Store News;7/14/97, Vol. 19 Issue 11, pCP1 

    Reports that Representative Henry Waxman has warned brand name pharmaceutical manufacturers that he will resist efforts by brand-name drug makers to create impediments to generic drug approvals under the 1984 Waxman-Hatch Act.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics